BioClinica, Inc. Partners With Mirada Medical for New Era of Molecular Image Analysis in Clinical Trials

NEWTOWN, PA and OXFORD, UK--(Marketwire - March 30, 2012) - BioClinica®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced a partnership with Mirada Medical, a leading provider of medical image analysis software. BioClinica will integrate Mirada’s XD3 software solution into its imaging core lab technology to further enhance its PET capabilities and expertise for molecular imaging trials.

Mirada Medical’s software provides unique tools and efficient workflows for the quantification and tracking of findings for major modalities including PET, CT, MR and MR/PET. After a careful evaluation of available molecular imaging solutions, BioClinica selected Mirada for its advanced image analysis capabilities and ability to handle not only PET images but CT and MRI as well. This will further enhance BioClinica’s image registration and fusion capabilities in studies where multiple modalities are utilized.

BioClinica’s strategy goes beyond a standard utilization of Mirada’s software by creating a strategic partnership that will foster innovation as the molecular imaging field continues to develop. BioClinica will integrate Mirada’s XD3 image analysis software platform into its processes and workflows, adopting an innovative design that will advance the clinical capabilities of BioClinica technologies such as BioPACS and BioREAD. These high-performing imaging workflow and processing programs will now have expanded capabilities to help trial sponsors harness the superior imaging results that are achievable through PET scans and multi-modal technology.

Through this partnership, BioClinica’s PET image processing capabilities will extend oncology clinical trials with support for the following features:

• Enhanced capabilities for PERCIST tumor response assessment criteria
• Normalization of uptake by body weight, lean body mass, or body surface area for SUV measurements
• Registration and fusion capabilities between PET, CT, and MR
• Customizable workflow and user interface to provide flexibility in the independent read design

“Adding Mirada technology to our oncology trial process takes BioClinica’s already robust imaging core lab services to a new level,” said Dr. Andy Dzik-Jurasz, BioClinica’s Senior Medical Director of Medical Affairs. “By adding XD3 to our workflow, BioClinica will offer the most sophisticated level of clinical analysis available for oncology PET scan image processing.”

“Mirada is delighted to partner with an innovative industry leader like BioClinica,” said Timor Kadir, Chief Science and Technology Officer at Mirada Medical. “We are excited to see BioClinica’s innovative utilization of XD3’s superior quantification and world class image fusion to achieve more accurate and reproducible results for their trial sponsors.”

As part of this partnership, Mirada Medical will present at BioClinica’s upcoming User Conference in October. The BioClinica User Conference consists of two days of valuable presentations, case studies and discussions designed to help BioClinica imaging core lab customers and eClinical solution users discover new ways to run faster, more efficient clinical trials. To learn more about the conference, visit http://www.bioclinica.com/User-Conference-2012.

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on Twitter at http://twitter.com/bioclinica.

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com

About Mirada Medical

Mirada Medical is a leading international brand in medical imaging. The company develops advanced software applications which help healthcare professionals use medical images more effectively and efficiently to improve cancer care. Mirada’s products are used across diagnostic radiology, molecular imaging, radiation oncology, medical oncology, tumor board and elsewhere.

Mirada specializes in simplifying technically complex image processing tasks, allowing clinicians to more confidently diagnose disease, assess response to treatment and plan radiation therapy or surgical intervention.

Mirada’s advanced software products are available throughout the world under its own brand, and on an OEM basis through a select number of the world’s leading healthcare companies.

Mirada Medical was originally spun out of the University of Oxford. The company’s technologies and products continue to be developed by their team of specialists, engineers and world-renowned scientists at Mirada’s world headquarters in Oxford, England.

Mirada Medical, Mirada XD3, Caseaccess and Casemeeting are all trademarks of Mirada Medical Ltd.

For more information, visit www.mirada-medical.com

Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

Press release: http://hugin.info/143183/R/1598606/504137.pdf